Related Experiment Video
Updated: Jun 27, 2025
A Protocol to Set Up Needle-Free Connector with Positive Displacement on Central Venous Catheter in Intensive Care Unit
Published on: July 13, 2019
Taurolidine and Heparin as Catheter Lock Solution for Central Venous Catheters in Hemodialysis
Timothy Nguyen1, Bernard C Camins2, David A Butler3
1Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY.
Insights
Taurolidine and heparin catheter lock solution significantly reduces catheter-related bloodstream infections (CRBSI) in hemodialysis patients. This novel approach offers a safer alternative to antimicrobial therapies for preventing CRBSI in patients requiring central venous catheters (CVCs).
Area of Science:
- Nephrology
- Infectious Diseases
- Medical Devices
Background:
- Increasing prevalence of end-stage renal disease necessitates hemodialysis, often requiring central venous catheters (CVCs).
- Catheter-related bloodstream infections (CRBSIs) are a significant cause of morbidity and mortality in hemodialysis patients.
- Existing CRBSI prevention methods like antimicrobial lock therapy raise concerns about resistance and adverse effects.
Purpose of the Study:
- To evaluate the efficacy of taurolidine and heparin catheter lock solution in preventing CRBSIs in hemodialysis patients.
- To assess the safety and effectiveness of this novel nonantimicrobial antiseptic lock solution.
Main Methods:
- A randomized, double-blind, phase 3 study (LOCK-IT-100 trial) involving 795 end-stage renal disease patients on hemodialysis with CVCs.
- Comparison of taurolidine and heparin lock solution against heparin alone as a control.
- Intraluminal use of the lock solution, followed by aspiration.
Main Results:
- Taurolidine and heparin lock solution demonstrated a 71% risk reduction in CRBSI compared to heparin alone (P = 0.0006).
- Consistent findings across other studies and systematic reviews indicate reduced CRBSI incidence with taurolidine lock solutions in adult and pediatric populations.
- The solution has both antimicrobial and anticoagulant properties, preventing microbial damage and biofilm formation.
Conclusions:
- Taurolidine and heparin catheter lock solution is a novel and effective preventive strategy for CRBSI in hemodialysis patients with CVCs.
- This represents significant therapeutic progress, offering a valuable option where CVCs are essential for life-saving treatment.
- The unique mechanism of action and favorable safety profile of taurolidine make it a promising alternative to traditional antimicrobial lock therapies.
Background:
Chronic kidney disease can lead to end-stage renal disease, and the prevalence is increasing. Many patients starting hemodialysis require central venous catheters (CVCs). Catheter-related bloodstream infections (CRBSIs) are a common complication and lead to significant morbidity and mortality. Interventions to prevent CRBSI include antimicrobial lock therapy but concern for the development of antimicrobial resistance and adverse effects. Nonantimicrobial antiseptics as catheter lock solutions have also been used. Taurolidine and heparin catheter lock solution is first approved by the Food and Drug Administration for the prevention of CRBSI in patients on hemodialysis. Taurolidine has a unique mechanism of action and favorable safety profile.
Mechanism Of Action, Pharmacodynamics, And Pharmacokinetics:
Taurolidine and heparin catheter lock solution have both antimicrobial and anticoagulant properties. Taurolidine is derivative of the amino acid taurine, and heparin is derived from porcine intestinal mucosa. Taurolidine not only damages microbial cell walls but also prevents the adherence of microorganisms to biological surfaces, preventing biofilm formation. Taurolidine and heparin catheter lock solution is intended to be used intraluminally within the catheter and should be aspirated. Because it is used locally, limited pharmacokinetic and pharmacodynamic data are available.
Clinical Trials:
The LOCK-IT-100 trial is a randomized, double-blind, phase 3 study, which included 795 end-stage renal disease patients on hemodialysis with CVC. Taurolidine and heparin was compared with the control heparin alone. The results of the study showed a 71% risk reduction in CRBSI for taurolidine and heparin arm (95% confident interval, 38%-86%, P = 0.0006). Other studies have also shown that taurolidine lock solution leads to decreased CRBSI episodes. Several systematic reviews and meta-analysis consisted of taurolidine in adult, and pediatric populations also showed reduction in the incidence of CRBSIs.
Therapeutic Advance:
Taurolidine and heparin lock solution represents a novel preventive strategy for those undergoing hemodialysis through a CVC by reducing the risk of CRBSI. This is significant progress because there are no other similar options available for patients for whom catheters are the only options for their life-saving treatment.
More Related Videos
08:51Author Spotlight: Hickman Catheter Use for Long-Term Vascular Access in a Preclinical Swine Model
Published on: March 31, 2023
09:38Femoral Arterial and Venous Catheterization for Blood Sampling, Drug Administration and Conscious Blood Pressure and Heart Rate Measurements
Published on: January 24, 2012
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:27Parentral Nutrition: Centeral and Peripheral Parental Nutrition
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
01:27Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
01:16Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia
One of the advantages of...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...